Venus Remedies is a pharmaceutical manufacturing company. The company provides fromulations in area of antibiotics and oncological therapecutics. The company has tow manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
Venus Remedies has received its first maketing authorization in Switzerland from Swiss drug authority - Swissmedic -- for Gemcitabine 200mg & 1g injection through Venus Pharma GmbH. This market approval of critically important oncology drug Gemcitabine Injection will help Venus to strengthen its oncology portfoilo.
The company is planning to launch this product in early next quarter within this fiscal year to expand its presence in the oncology spaces. Venus Pharma GmbH the German subsidiary will carry out complete analysis of the goods. The product will be launched in Switzerland market by Swiss Pharma GmbH with whom Venus had a marketing tie up.
The promoters holding in the company stood at 37.51% while Institutions and Non-Institutions held 8.69% and 53.80% respectively.
The BSE group 'B' stock of face value Rs 10 had touched a 52 week high of Rs 350.00 on 28-Apr-2014 and a 52 week low of Rs 162.30 on 20-Aug-2013
The current prices of share is 264.00, up by 14.15 points from its previous closing of Rs 249.85 on the BSE
The promoters holding in the company stood at 37.51% while Institutions and Non-Institutions held 8.69% and 53.80% respectively.
The BSE group 'B' stock of face value Rs 10 had touched a 52 week high of Rs 350.00 on 28-Apr-2014 and a 52 week low of Rs 162.30 on 20-Aug-2013
The current prices of share is 264.00, up by 14.15 points from its previous closing of Rs 249.85 on the BSE
No comments:
Post a Comment